Back to today’s briefing

Story perspectives

Inhaled Heparin Halves Ventilation Needs for COVID Patients

9/30/2025

43 9

Summary

Story summary

The Australian National University (ANU)-led study shows inhaled heparin halves ventilation needs and lowers mortality in seriously ill COVID-19 patients.
The trial enrolled nearly 500 patients across six countries.
Heparin, used for clots, also has antiviral, anti-inflammatory, anti-coagulant properties.
Researchers say inhaled heparin could treat respiratory infections including pneumonia and influenza.
Findings were presented September 28, 2025.

1 of 1

Story summary

The Australian National University (ANU)-led study shows inhaled heparin halves ventilation needs and lowers mortality in seriously ill COVID-19 patients.
The trial enrolled nearly 500 patients across six countries.
Heparin, used for clots, also has antiviral, anti-inflammatory, anti-coagulant properties.
Researchers say inhaled heparin could treat respiratory infections including pneumonia and influenza.
Findings were presented September 28, 2025.